Celgene Corporation (NASDAQ: CELG) has recently received a number of price target changes and ratings updates:

  • 8/9/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $175.00 price target on the stock.
  • 8/1/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at Cann. They now have a $175.00 price target on the stock. They wrote, “Celgene announced that Idhifa (enasidenib/AG-221) was granted approval from FDA for the treatment of adult patients with relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test. It was reported that FDA approval was based on the clinical data from an open-label, single-arm, multicenter, two-cohort clinical trial of adult patients with relapsed or refractory AML with an IDH2 mutation (Study AG221-C-001, NCT01915498). Idhifa was approved concurrently with the Abbott RealTime IDH2 companion diagnostic test, which is FDA-approved as an aid in identifying AML patients for treatment with Idhifa.””
  • 7/31/2017 – Celgene Corporation was upgraded by analysts at Argus from a “hold” rating to a “buy” rating. They now have a $160.00 price target on the stock, up previously from $96.93.
  • 7/31/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $160.00 price target on the stock.
  • 7/31/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $175.00 price target on the stock, up previously from $148.00.
  • 7/28/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $160.00 price target on the stock, up previously from $150.00.
  • 7/28/2017 – Celgene Corporation is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $155.00 price target on the stock.
  • 7/28/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $160.00 price target on the stock, up previously from $152.00.
  • 7/28/2017 – Celgene Corporation had its “hold” rating reaffirmed by analysts at Barclays PLC. They now have a $135.00 price target on the stock.
  • 7/27/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $150.00 price target on the stock.
  • 7/27/2017 – Celgene Corporation was given a new $160.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/27/2017 – Celgene Corporation was given a new $156.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 7/26/2017 – Celgene Corporation was given a new $134.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 7/21/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $162.00 price target on the stock.
  • 7/19/2017 – Celgene Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Celgene’s key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration. Celgene continues to progress with its label expansion efforts and pipeline development. Revlimid was approved as a single agent for maintenance therapy in adult patients with NDMM following ASCT both in the U.S. and EU. Celgene’s NDA for Idhifa for relapsed and/or refractory acute myeloid leukemia was granted Priority Review with a PDUFA action date of Aug 30, 2017. Label expansion of drugs would boost revenues significantly. Moreover, shares of Celgene have outperformed the industry in the past one year. However, Celgene is highly dependent on Revlimid. Otezla sales in the first quarter were impacted by managed care dynamics that drove lower total marketplace prescriptions for psoriasis therapies although the pressure should ease as the year goes.”
  • 7/18/2017 – Celgene Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $151.00 price target on the stock. According to Zacks, “Celgene’s key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration. Celgene continues to progress with its label expansion efforts and pipeline development. Revlimid was approved as a single agent for maintenance therapy in adult patients with NDMM following ASCT both in the U.S. and EU. Celgene’s NDA for Idhifa for relapsed and/or refractory acute myeloid leukemia was granted Priority Review with a PDUFA action date of Aug 30, 2017. Label expansion of drugs would boost revenues significantly. Moreover, shares of Celgene have outperformed the industry in the past one year. However, Celgene is highly dependent on Revlimid. Otezla sales in the first quarter were impacted by managed care dynamics that drove lower total marketplace prescriptions for psoriasis therapies although the pressure should ease as the year goes.”
  • 7/14/2017 – Celgene Corporation was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $149.76 price target on the stock.
  • 7/14/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $150.00 price target on the stock.
  • 7/11/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $160.00 price target on the stock.
  • 7/10/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at Bank of America Corporation. They now have a $153.00 price target on the stock.
  • 7/6/2017 – Celgene Corporation was given a new $148.00 price target on by analysts at Credit Suisse Group. They now have a “buy” rating on the stock.
  • 7/6/2017 – Celgene Corporation was given a new $160.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “Acquisition of worldwide Rights to BeiGene,s (NASDAQ: BGNE, NC) excluding Asia, PD-1 inhibitor for solid tumors, BGB-A317, enhances CELG’s oncology portfolio and augments its immuno-oncology efforts.””
  • 7/6/2017 – Celgene Corporation was given a new $150.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “buy” rating on the stock.
  • 7/6/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $139.00 price target on the stock.
  • 7/4/2017 – Celgene Corporation was upgraded by analysts at Vetr from a “hold” rating to a “strong-buy” rating. They now have a $149.76 price target on the stock.
  • 6/30/2017 – Celgene Corporation was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating. They now have a $131.70 price target on the stock, up previously from $96.93.
  • 6/26/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at William Blair.
  • 6/22/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at Leerink Swann.
  • 6/21/2017 – Celgene Corporation was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/16/2017 – Celgene Corporation was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating. They now have a $150.00 price target on the stock, up previously from $94.42. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 6/14/2017 – Celgene Corporation was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 6/14/2017 – Celgene Corporation was given a new $148.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.

Shares of Celgene Corporation (NASDAQ:CELG) traded down 3.84% during midday trading on Thursday, reaching $130.37. The company had a trading volume of 4,220,970 shares. The company has a market capitalization of $101.99 billion, a P/E ratio of 40.37 and a beta of 1.89. The company has a 50-day moving average price of $134.30 and a 200 day moving average price of $124.13. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter last year, the company earned $1.44 EPS. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. Equities analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

In related news, insider Robert J. Hugin sold 175,970 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the transaction, the insider now owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 235,255 shares of company stock valued at $31,377,042. 0.95% of the stock is owned by corporate insiders.

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.